JBIO•Jade Biosciences expects to start the EVERGREEN Phase 3 trial of JADE101 for IgA nephropathy in the fourth quarter of 2026, ahead of schedule. Interim data from its JUNIPER Phase 2 trial are now expected in the second quarter of 2027.
Jade Biosciences expects to initiate its EVERGREEN Phase 3 trial of JADE101 for IgA nephropathy ahead of schedule in the fourth quarter of 2026. Interim data from the ongoing JUNIPER Phase 2 trial are now expected in the second quarter of 2027.
The company plans to present study-design posters on October 24, 2026, at ASN Kidney Week in Denver. A model-based assessment scheduled for October 22 is intended to inform dose selection, assess anticipated responses to APRIL inhibition and support accelerated development.
